Longer-term follow up data (median of 11.5 months) from the Phase 1b portion of the CARTITUDE-1 study demonstrated 100% overall response rate, 86% stringent complete response rate and a 9 month progression free survival rate of 86%. Somerset, N.J., May 13, 2020 – Legend Biotech Corporation (“Legend”) announced today updated results from the Janssen Pharmaceutical […]
Collaboration focuses on advancing the next generation of T-cell products for the treatment of solid tumors Somerset, NJ, USA and Tokyo, Japan; May 4, 2020 – Legend Biotech Corporation (“Legend”), a global clinical stage biopharmaceutical company engaged in the discovery and development of novel cell therapies, announced today that Legend and Noile-Immune Biotech, Inc. (“NoileImmune”), […]
Somerset, NJ, April 1, 2020 – Legend Biotech Corporation (Legend), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has raised $150.5 million in Series A financing. Proceeds from the financing will be used to advance the research and development […]
Somerset, NJ (March 9, 2020): — Legend Biotech Corporation today announced that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares, representing its ordinary shares. The number of American depositary shares to be offered […]
Piscataway, NJ, January 28, 2020 – Legend Biotech announced that, according to the terms and conditions of an agreement with Janssen Biotech, Inc. (Janssen), the fourth milestone payment has been achieved relating to the U.S. clinical development of the B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M (JNJ-68284528 (JNJ-4528)). “We are pleased […]
SOMERSET, N.J.— (BUSINESS WIRE)—August 30, 2021—Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10. Ying Huang, Chief Executive Officer and Chief Financial Officer, […]
SOMERSET, N.J.—(BUSINESS WIRE)—August 23, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported its 2021 second quarter unaudited financial results. “We have made exciting progress in advancing our first investigational CAR-T therapy cilta-cel in the […]
New Cell Therapy Facility in Belgium Establishes Manufacturing Presence in the European Union New facility builds upon Legend Biotech’s collaboration with Janssen to advance the manufacturing of investigational CAR-T therapy ciltacabtagene autoleucel (cilta-cel), being developed for the treatment of multiple myeloma. SOMERSET, N.J.— June 22, 2021— Legend Biotech Corporation (Legend Biotech, NASDAQ: LEGN), a global […]
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings Longer-term results from the Phase 1b/2 CARTITUDE-1 study demonstrated 98 percent overall response rate, 80 percent stringent complete response rate and 66 percent progression free survival […]
SOMERSET, N.J.— (BUSINESS WIRE)— May 26, 2021 —Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted […]
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.